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• Canada’s adverse drug reaction (ADR) frameworks are grounded in the Protecting Canadians from 
Unsafe Drugs Act (Vanessa's Law) and offers changes to the Food and Drug Act. 
• Pharmacovigilance is a key safeguard in protecting patients, as potential adverse drug reactions (ADRs) 
are estimated to cause 3-7% of hospital admissions.
• Methodologies range from variations of case-controls studies to data mining/predictive analytics.
• Several key metrics, including the Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), 
amongst others, are commonly used to establish a threshold for further investigation.
• Adequate policy frameworks provide the foundation for proper data collection and sound statistical 
analysis (e.g. mandatory reporting and centralized ADR databases). 
• To identify the statistical metrics and 
methods used in determining  
pharmacotherapy recalls, with a focus on 
Canada’s existing framework.
• To investigate the advantages and 
disadvantages of specific approaches 
employed in signals management.
1. School of Health Studies, The University of Western Ontario, London, ON 
Data Collection:
Ø A literature search was conducted with 
PubMed, SCOPUS, and MEDLINE. 
Ø Grey literature from the FDA, Health 
Canada, and the European Medicines 
Agency, mainly white papers, were also 
included in this review. 
Data Analysis:
Ø Data charting as per JBI’s Manual for 
Evidence Synthesis.
Ø PICO data compared with each health 
agency’s methods and measures. 
Ø Canada’s ADR methods was examined 









Data Collection for ADRs 
- In Canada, ADR reporting is mandatory only for hospitals,  while independent clinics and private care facilities 
report on a voluntary basis. 
- Hospitals constitute a small portion of ADR reports (6%), most come from Marketing Authorization Holders (MHA).
- Data collected is stored in HC’s central database under the Canada Vigilance Program  (now named MedEffect).
- Foreign ADR reports are also examined; foreign reports outnumber domestic reports by a factor of 12x. 
- Other sources of ADR reports include case studies from the literature, WHO Vigimed, Periodic Safety Update 
Reports (PSURs), amongst others. 
Signals Generation / Data 
Analysis 
- HC relies on the Proportional Reporting Ratio (PRR) to trigger manual investigation.
- Specific statistical methods used by Health Canada are not public, although they cite the use of Chi-squared, 
likelihood ratio, amongst other tests. 
- There appears to be no standardized tests (or combination of tests) or methods based on classes of drugs, 
although this is a commonality shared with EU EMA and the US FDA. 
- The current pipeline for signals generation and data analysis may take months to complete while the predictive 
value of PRR/ROR is most effective in the first year. 
- Causal relationship are established and weighed against potential downside and benefits prior to risk mitigation; 
this is standard practice across all pharmacovigilance agencies. 
Risk Mitigation / Market 
Communications 
- Once a risk to patients have been established, a wide spectrum of options are available (e.g. total recall, label 
changes, advisories, etc.) 
- Additional studies may be conducted, or MAHs may be required to conduct additional post-market monitoring 
activities (e.g. PSURs).
• The existing regulatory framework in Canada does not enable adequate data collection. Since only hospitals are required to report 
ADRs, a large part of the medical establishment (e.g. private clinics, LTC home) are excluded. This may contribute to unintentional 
widespread under-reporting and affect HC’s ability to evaluate ADRs and conduct signals management. 
• There is a disproportionate influence from industry in determining what ADRs are reported to HC. This is turn, poses a systemic conflict 
of interest as statistical analyses are rendered less effective because reports may be skewed. 
• Unlike the EU EMA, there lacks transparency with how HC analyzes spontaneous ADR reports.
• There needs to be an expedited means to consolidate all available sources of data into a predictive platform that will automatically 
generate and evaluate ADR signals since the predictive value of reporting ratio drops off after 1 year (according to EU EMA).
• There appears to be inadequate post-market risk management. When a drug recall is determined, there are no effective means to 
communicate to healthcare providers and patients; this issue is most widespread with minor ADRs. 
• There remains a need to validate different statistical metrics used in signals management. This issue is not unique to Canada, but for 
the field of pharmacovigilance. The EU EMA is currently a leader in validating their research methods.
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• Develop an understanding and compare 
the difference between approaches used 
in signals management from the US FDA, 
Health Canada, and EU EMA.
• Translate possible strategies into a 
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